This chapter details the therapy protocols involving ibogaine utilized at The Mission Within (https://missionwithin.org) in Baja California, Mexico, as described by its founder and research director, Dr. Martin Polanco, along with psychedelic preparation/integration counselor and therapeutic facilitator, Dr. Mia Black. The chapter describes: Their personal development as ibogaine therapists and...
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N , N ‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g. ibogaine, ketamine and esketamine; and other atypicals e.g. dextromorphan/bupropion, esmethadone....
Abstract Psychedelic-assisted groups (PAGs) indicate promise with clients that do not respond to traditional talk therapy. While encouraging, in the U.S., societal perceptions of psychedelics and concern of practicing outside one’s scope may cause practitioners to hesitate. To illustrate the potential effectiveness of PAGs, this article has three parts. First is a historical overview of...
Abstract Depression and anxiety are disabling and high incidence mental disorders characterized by phenotypic heterogeneity. Currently available treatments show severe limitations. Thus, there is an urgent need for effective treatments in this population. In the search for novel rapid-acting antidepressants, the psychedelic psilocybin has emerged as a promising therapy in several clinical...
Sexual and gender minority (SGM) individuals experience disproportionately high rates of depression, anxiety, trauma, and discrimination, yet remain underrepresented in psychedelic research. This prospective, naturalistic study explored the impact of an ayahuasca retreat experience on mental health, quality of life, and spiritual well-being among SGM participants. Nineteen individuals attending...
ABSTRACT Joshua Falcon's comprehensive synthesis, “Anthropology of Psychedelics,” significantly addresses gaps in psychedelic anthropology, particularly urban practices in the Global North and decolonial considerations. This commentary expands upon Falcon's work by incorporating recent clinical studies and sociocultural analyses that reinforce his proposed directions. Empirical evidence from...
Innovative formulations of N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) enable parenteral and intranasal delivery, respectively. These delivery systems overcome limitations of poor bioavailability and rapid metabolism, offering rapid-onset, short-duration therapeutic effects. The compositions support controlled psychedelic interventions for psychiatric...
A recent randomized, double-blind, placebo-controlled, parallel-group trial (NCT02061293) found that psilocybin-assisted therapy significantly improved drinking outcomes compared to an active placebo in adults with alcohol use disorder (AUD). In this secondary analysis, we assessed whether psilocybin-assisted therapy improved self-compassion and whether these changes predicted drinking...
Mental health disorders and associated economic impact continue to rise domestically and globally. In 2023, to expand treatment options for individuals suffering Treatment Resistant Depression (TRD), the Therapeutic Goods Administration (TGA) of Australia has permitted psychiatrist lead psilocybin-assisted psychotherapy. Psilocybin, a psychedelic tryptamine found naturally in psychedelic...
Professor Stephen Ross is a prominent faculty member in the Departments of Psychiatry and Child and Adolescent Psychiatry at the New York University (NYU) Grossman School of Medicine who has transformed the landscape of psychedelic research since 2006. In this Genomic Press Interview, Dr. Ross reveals how as co-director of the NYU Langone Center for Psychedelic Medicine and director of its...